# Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

> **NCT01217437** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 108 (actual)

## Conditions studied

- Central Nervous System Neoplasm
- Pineoblastoma
- Recurrent Medulloblastoma
- Recurrent Primitive Neuroectodermal Tumor
- Refractory Medulloblastoma
- Refractory Peripheral Primitive Neuroectodermal Tumor

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Irinotecan Hydrochloride
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01217437
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-22
- **Primary completion:** 2017-12-31
- **Final completion:** 2021-06-30
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01217437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01217437, "Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01217437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*